jnj-54452840
Peptideexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2013 (NCT01902550)
Timeline
Indications
Mechanism of action
- Beta-1 adrenergic receptorINHIBITOR
ADRB1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- jnj-54452840
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01798745 | Phase 2 | Nov 1, 2014 | Johnson and Johnson |
| NCT01809353 | Phase 1 | Jul 1, 2013 | Johnson and Johnson |
| NCT01902550 | Phase 1 | Jul 1, 2013 | Johnson and Johnson |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 3 | 3 | 2 | 2013 |
1 organizations
Page 1 / 1